Trials / Withdrawn
WithdrawnNCT06581055
A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes
A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes Who Discontinued Treatment With Luspatercept or Epoetin Alfa and the COMMANDS Trial
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to collect real-world data on treatment patterns and clinical outcomes for participants who discontinued Luspatercept or epoetin alfa treatment and discontinued the COMMANDS trial (NCT03682536) utilizing existing data from patient medical records.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Luspatercept | As per COMMANDS Trial (NCT03682536) study protocol |
| DRUG | Epoetin Alfa | As per COMMANDS Trial (NCT03682536) study protocol |
Timeline
- Start date
- 2024-11-30
- Primary completion
- 2025-03-30
- Completion
- 2025-03-30
- First posted
- 2024-08-30
- Last updated
- 2024-10-09
Locations
1 site across 1 country: Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06581055. Inclusion in this directory is not an endorsement.